AI Summary
This content indicates that the risk of developing secondary cancers after CAR T-cell therapy is similar to the risk associated with other standard cancer treatments. The information is based on a systematic review and meta-analysis.
The frequency of second primary malignancies (SPMs) arising in cancer survivors following treatment with CAR T-cell therapy was statistically comparable to the frequency of SPMs following other standard-of-care therapies, according to a systematic review and meta-analysis.